A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
Status:
Completed
Trial end date:
2020-05-13
Target enrollment:
Participant gender:
Summary
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis
patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin
in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for
dosing with erythropoietin and intravenous iron in these patients.